That's it! First mover in Cell therapies for a CDH-17 target and a 3rd generation one at that. Refined to optimise tumour eradication through Penn’s 10 year development. Below graphs demonstrate the evolution of each generation. Only after complete optimisation it was licensed by CHM. That green line looks pretty compelling and a huge improvement on the 2nd Gen. Could it have the potency to penetrate the allusive TME (tumour microenvironment). We will find out in the not too distant future.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $9.116K | 2.278M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 4987697 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 13474013 | 20 |
View Market Depth
| Last trade - 12.15pm 24/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |